19th European Symposium on Radiopharmacy and Radiopharmaceuticals





FINAL PROGRAMME

April 05-08, 2018 • Groningen, Netherlands

TABLE OF CONTENTS

WELCOME ADDRESS

Dear Colleagues and Friends,

It is our pleasure to welcome you to Groningen to attend the 19th European Symposium on Radiopharmacy and Radiopharmaceuticals in April 2018.

Groningen, an old Hanseatic city with 180.000 inhabitants including 40.000 students, has an old University from 1614, a University Medical Center of 1300 beds and a referral base of 2.5 Million inhabitants from the Northern provinces in the Netherlands. As a result, Groningen is a very cozy city with many hotels, bars and restaurants and almost everything is within walking distance. The MartiniPlaza venue is located at about 20 min walking from the city center and the railway station and is very conveniently located for arrivals by car. Groningen can be easily reached by car and train. For those who travel by plane, the closest airport is Amsterdam Schiphol connecting to Groningen with trains leaving every 30 min. The train ride takes 2 hours.

The Department of Nuclear Medicine and Molecular Imaging in Groningen has a longstanding tradition (>40 years) in the development and production of radiopharmaceuticals and is very active within different activities in the Netherlands and the EANM with respect to radiopharmaceuticals.

The current infrastructure includes an IBA C18 cyclotron, a fully equipped GMP-PET laboratory including 17 hot cells and GMP-SPECT cleanrooms also including a facility for ^{89}Zr-labelling.

Therefore, Groningen is the ideal location to host an attractive and innovative Radiopharmacy meeting covering all scientific and regulation aspects. We are looking forward to host you and set the scene for fruitful meetings and discussions.

Welcome to Groningen!

Philip Elsinga
Erik de Vries
Gert Luurtsema
Hendrikus Boersma

SCIENTIFIC COMMITTEE

Philip Elsinga	*Netherlands*
Antony Gee	*United Kingdom*
Petra Kolenc-Peitl	*Slovenia*
Peter Laverman	*Netherlands*
Tom Mindt	*Austria*

LOCAL ORGANISING COMMITTEE

Philip Elsinga
Erik de Vries
Gert Luurtsema
Hendrikus Boersma

ORGANISING SECRETARIAT

EANM Executive Secretariat
Andreas Felser
Petra Neubauer
Schmalzhofgasse 26
1060 Vienna, AUSTRIA
Tel.: +43-(0)1 890 44 27
Fax: +43-(0)1 890 44 27 - 9
Email: office@esrr.info
URL: www.esrr.info

CONGRESS VENUE

MartiniPlaza
L. Springerlaan 2
9702 KA Groningen, NETHERLANDS
Tel.: +31 (0)50 5222 621
URL: https://www.martiniplaza.nl/

ESRR'18 is organised under the auspices of the EANM

EXHIBITORS & SPONSORS

We would like to thank all exhibitors and sponsor of the ESRR 2018 for their support!

ABX advanced biochemical compounds

ABX-CRO advanced pharmaceutical services

COMECER S.p.A.

Elysia-raytest

GE Healthcare

IBA SA (ION BEAM APPLICATION)

IDB Holland BV

iPHASE

IRE ELIT

ITM Isotopen Technologien München AG

LabLogic Systems Limited

MILabs b.v.

Molecubes

NRG

ORA-NEPTIS

Rotem GmbH

ROTOP

Scintomics GmbH

Trasis SA

Von Gahlen Nederland B.V.

GENERAL INFORMATION (A-Z)

Bicycle Rental

There are various locations in Groningen for hiring a bicycle. OV bicycles are available for hire at the Groningen main railway station, Winschoten station and the Euroborg P+R (P3). The province has numerous wonderful options for cycling, such as routes through the Westerkwartier or along the Lauwersmeer Lake. Enjoying the Oldambt and expansive skies of the highland is even better from your bike. Peddel & Pedaal is a very special way to explore Westerwolde, with various bicycle routes combined with a canoe trip.

Certificate of Attendance

Upon arrival all registered delegates will receive a certificate of attendance.

Climate

The daytime temperatures in April linger between 3° - 13° Celsius.

Credit cards

All major credit cards, including Eurocard, Diners, VISA and Mastercard are accepted in restaurants, hotels, shopping centers and stores.

Currency

The official currency in in the Netherlands is EUR (€). You can exchange your currency without any limits for total amount at all banks and exchange offices in Groningen. When exchanging your currency, you will need your passport or official ID-card. If you do not have it with you, the bank may refuse to exchange your currency

Electricity

The power supply in the Netherlands is 220/240 Volt-current. Most electric outlets adhere to the continental standard (Schuko). Appliances from North America require a transformer and British appliances require an adaptor for the two-pin sockets in use in the Netherlands.

Museums

The Groningen Museum, a work of art in itself, is one of the most beautiful and special museums in the Netherlands. There are various museums in the city and province that highlight all of the aspects of Groningen, for example the Stripmuseum (Comic Strip Museum), or the Grafisch (Graphic) Museum. An art-loving city such as Groningen naturally has many galleries with regularly changing exhibitions all year round.

Restaurants & Pubs

Groningen has a variety of pubs and a number of restaurants which have been awarded a Michelin Star; all-night restaurants where the kitchens are open even after midnight, and in particular many pubs where your food is served.

Secretariat & Registration desk

The registration desk will be open:

Thursday, April 05, 2018	17:00-20:00
Friday, April 06, 2018	08:00-17:30
Saturday, April 07, 2018	08:00-17:30
Sunday, April 08, 2018	08:00-12:00

Shopping

From Tuesday till Friday most stores are opened from 10 AM until 6 PM. On Saturday you can shop until 5 PM. On Monday mornings, most shops in the city centre are closed until 1 PM (this does not apply to all companies). On weekdays, most shops are open until 6 PM. In Groningen you can shop seven days per week – Shops are now also opening their doors on Sunday. Groningen shops have late night shopping on Thursday evenings when many shops are open until 9 pm.

Taxes & Tipping

The standard tax rate is 21%, however, some services such as hotel, food and transport have a reduced rate of 6%. Most services do not include tipping. In higher class restaurants it is common to give up to 10% of the total. For any other services (taxi, restaurants, hotel) it is up to you how much you want to give.

Time zone

Central European Time (CET) is 1 hour ahead of Coordinated Universal Time (UTC).

Delegate Registration Fees include:

- Access to all scientific session
- Access to poster exhibition
- Access to industry exhibition
- Free copy of all congress documentation
- Certificate of attendance
- Lunch- April 06 & 07, 2018
- Coffee breaks April 06, 07 & 08, 2018
- Invitation to the Opening Ceremony and Welcome Reception – April 05, 2018
- Invitation to the Closing Ceremony – April 08, 2018
- Conference Dinner – April 06, 2018
- Social Dinner – April 07, 2018

Accompanying Person Registration Fees include:

- Invitation to the Opening Ceremony and Welcome Reception – April 05, 2018
- Invitation to the Closing Ceremony – April 08, 2018
- Conference Dinner – April 06, 2018
- Social Dinner – April 07, 2018

PROGRAMME OVERVIEW

THURSDAY, APRIL 05, 2018

19:30-19:50	Opening Ceremony & Welcome Meeting
19:50-20:25	Welcome Lecture – Life: How did it originate and can we synthesize it?
20:30-22:00	**Welcome Reception**

FRIDAY, APRIL 06, 2018

08:30-10:05	Session I – Radiometals and Arthropods
10:05-10:35	**Poster Viewing Session**
	Coffee Break
10:35-12:35	Session II – Radiolabelling Smorgasbord
12:35-14:05	Lunch Break
14:05-15:40	Session III – In Vivo Targetry
15:40–16:30	**Poster Viewing Session**
	Coffee Break
16:30-17:30	Session IV – Kill the Disease, not the Patient

SATURDAY, APRIL 07, 2018

08:30-10:15	Session V – In Vivo Archery
10:15-11:00	**Poster Viewing Session**
	Coffee Break
11:00-12:45	Session VI – Malignant Malady Imaging
12:45-14:15	Lunch Break
14:15-15:50	Session VII – Seek and Destroy
15:50-16:30	**Poster Viewing Session**
	Coffee Break
16:30-17:30	Session VIII – The Art of the Drug Makers

SUNDAY, APRIL 08, 2018

08:30-10:30	Session IX – Product Scrutiny
10:30-11:00	**Poster Viewing Session**
	Coffee Break
11:00-12:35	Session X – Seek and Destroy Revisited
12:35-13:15	Highlights/Closing
13:15	**Farewell Lunch**

HIGHLIGHTS

Invited Lectures

Life: How did it originate and can we synthesize it?	*S. Otto, Netherlands*
Lecture 1: Cyclotron produced radiometals	*F. Alves, Portugal*
Lecture 2: In vivo Click Chemistry	*R. Rossin, Netherlands*
Lecture 3: Basics in kinetic modelling	*S. Krämer, Switzerland*
Lecture 4: Safety assessment requirements for radiopharmaceuticals for first in human studies (Toxicity and allometric upscaling)	*M. Behe, Switzerland*
Lecture 5: Transfer of preclinical dosimetry to humans	*M. Bardies, France*
Lecture 6: Neuroimaging	*I. Law, Denmark*
Lecture 7: Prostate cancer imaging: choline, PSMA, GRPR	*F. Verzijlbergen, Netherlands*
Lecture 8: Debate/Discussion - 68Ga-, 18F- or 99mTc-PSMA	*A. Windhorst, Netherlands* *S. Terry, United Kingdom* *M. de Jong, Netherlands*
Lecture 9: Immunocheckpoints	*A. Awada, Belgium*
European Pharmacopoeia: It is about Quality	*E. Pel, France*
New monographs and other ongoing projects	*T. Kroon, The Netherlands*
Lecture 10: Preparation from generators, kits and cyclotron produced nuclides - regulatory consequences	*R. Schulze, Germany*
Lecture 11: Changes in radiotracer production from the beginning to beyond 2020 – did we get better?	*P. Elsinga, Netherlands*
Lecture 12: True whole body dynamic PET - opportunities and challenges	*T. Jones, United Kingdom*
Lecture 13: Do we need radiochemists in the future?	*D. Vugts, Netherlands*

Invited Lectures are marked within the scientific programme in light blue.

Social Programme

Thursday, April 05, 2018
20:30 Welcome Reception (Congress Venue)

Friday, April 06, 2018
19:00 Conference Dinner at MartiniPlaza

Saturday, April 07, 2018
18:30 Meeting Point at MartiniPlaza for the busses
19:00 Social dinner at de Rietschans

Sunday, April 09, 2018
13:25 Farewell Lunch (Congress Venue)

SCIENTIFIC PROGRAMME

Thursday, April 05, 2018

19:30	**Opening Ceremony & Welcome Meeting**	***P. Elsinga, Netherlands / M. Patt, Germany***
19:50	Life: How did it originate and can we synthesize it?	*S. Otto, Netherlands*
20:30	**Welcome Reception**	

Friday, April 06, 2018

08:30	**Session I – Radiometals and Arthopods**	***T. Mindt, Austria / M. Figols de Borboza, Brazil***
08:30	Lecture 1: Cyclotron produced radiometals	*F. Alves, Portugal*
09:15	OP01 Novel Acyclic Chelators for 89Zr and	*B. Guérin, Canada*
09:27	OP02 - Improving pretargeting by applying multimerisation on a cyclic chelating scaffold	*D. Summer, Austria*
09:39	OP03 99mTc-radiolabeling of a poorly soluble protein, a variable heavy chain antibody domain targetingpancreatic b-cells	*M. Ahmadi, France*
09:51	OP04 - Synthesis of PET radiopharmaceuticals for cell radiolabelling using anion exchange column and cell labelling	*A. Socan, Slovenia*
10:05	**Coffee Break & Poster Viewing Session**	

10:35	**Session II – Radiolabelling Smorgasbord**	***E. de Vries, Netherlands / K. Kopka, Germany***
10:35	Lecture 2: In vivo Click Chemistry	*R. Rossin, Netherlands*
11:20	OP05 - Synthesis of 18F-AmBF3-losartan and preliminary in vitro evaluation as a novel AT1R PET radioligand in Oncology	*M. Sahylí Ortega Pijeira, Brazil*
11:32	OP06 - Time is Money and Radiation Burden - a carbon-11 'two-in-one-pot' production system	*C. Philippe, Austria*
11:44	OP07 - 18F-labelled BODIPY-steroid hormone conjugates as potential bimodal PET and fluorescence receptor imaging agents	*J. van Lier, Canada*
11:56	OP08 - Copper-mediated radiofluorination of aryl pinacol boronates in the presence of pyridinium sulfonates	*D. Antuganov, Russia*
12:08	OP09 - Development of biocompatible and functionalised polymer nanoparticles for the specific vectorisation of an imaging agent	*N. Lepareur, France*
12:20	OP10 - Development of a new generation propylene cross-bridged chelator as versatile platform for antibody radiolabeling with Cu-64	*S. Sarkar, South Korea*
12:35	**Lunch Break**	

14:05	**Session III – In Vivo Targetry**	***P. Laverman, Netherlands / S. Krämer, Switzerland***
14:15	Lecture 3: Basics in kinetic modelling	*S. Krämer, Switzerland*
14:50	OP11 - Pseudomonas aeruginosa infection imaging with Ga-68 labelled pyoverdine	*M. Petrik, Czech Republic*
15:02	OP12 - Modifying the siderophore triacetylfusarinine C for molecular imaging applications	*K. Kaeopookum, Austria*
15:14	OP13 - In vitro and in vivo comparison of the novel 89Zr chelator DFO-cyclo* with DFO	*R. Raavé, Netherlands*
15:26	OP14 - Characterization by Radio-HPLCS of Cell Effluxes and Cell Extracts of 99mTc-HMPAO Human Leukocytes	*T. Martinez, Spain*
15:40	**Meet the Author Poster Viewing Session**	

16:30	**Session IV – Kill the Disease, not the Patient**	***M. Behe, Switzerland / A. Windhorst, Netherlands***
16:30	Lecture 4: Safety assessment requirements for radiopharmaceuticals for first in human studies (Toxicity and allometric upscaling)	*M. Behe, Switzerland*
17:00	Lecture 5: Transfer of preclinical dosimetry to humans	*M. Bardies, France*
17:30	Round Table/Discussion	

Saturday, April 07, 2018

08:30	**Session V – In Vivo Archery**	***G. Luurtsema, Netherlands / R. Krasikova, Russia***
08:30	Lecture 6: Neuroimaging	*I. Law, Denmark*
09:15	OP15 - In vivo imaging of mGluR1 neuroreceptor kinetics in mouse brain with [11C]ITDM microPET	*S. Korat, Belgium*
09:27	OP16 - Anesthesia affects P-glycoprotein function at the Blood-Brain Barrier: A PET study with [18F] MC225 in rats	*L. Garcia Varela, Groningen*
09:39	OP17 – An ^{18}F-labeled derivative of baclofen for imaging GABAB receptors in mouse brain	*A. Horti, United States*
09:51	OP18 - Measurement of blood brain barrier transport using radiolabeled antibodies	*G. Charest, Canada*
10:03	OP19 - Synthesis and 18F-Radiolabelling of Novel Benzoimidazotriazines for Imaging of Phosphodiesterase 2A (PDE2A)	*R. Ritawidya, Germany*
10:15	**Meet the Author Poster Viewing Session**	

10:45	**Session VI – Malignant Malady Imaging**	***P. Kolenc Peitl, Slovenia / A. Rey, Uruguay***
10:45	Lecture 7: Prostate cancer imaging: choline, PSMA, GRPR	*F. Verzijlbergen, Netherlands*
11:30	Lecture 8: Debate/Discussion - 68Ga-, 18F- or 99mTc-PSMA *S. Terry* (Ga-68), *A. Windhorst* (F-18), *M. de Jong* (Tc-99m)	
11:42	OP20 - 64Cu-labelled anti-miRNA peptide nucleic acids as probes for molecular imaging of miRNA expression	*M. Asti, Italy*
11:54	OP21 - Correlation between 89Zr-DFO-Trastuzumab-DM1 Delivery versus the Cytotoxicity and Response of T-DM1 on HER2 Expressing Breast Cancer Xenografts	*N. Alsaden, Toronto*
12:06	OP22 - Physicochemical and in vitro evaluation of a 99mTc labelled NPY1 short analogue as potential breast cancer imaging agent	*A. Rey, Uruguay*
12:45	**Lunch Break**	

14:15	**Session VII – Seek and Destroy**	***S. Todde, Italy / H. Audrain, Denmark***
14:15	Lecture 9: Immunocheckpoints	*A. Awada, Belgium*
15:00	OP23 - 177Lu-DOTA-MGS5: the long-awaited theranostic probe for targeting cholecystokinin-2 receptor expression in medullary thyroid carcinoma and other tumours	*M. Klingler, Austria*
15:12	OP24 - In vivo evaluation of biocompatible 99mTc-bisphosphonate-coated MNPs designed as potential theranostic agents	*M. Mirkovic, Serbia*
15:24	OP25 - In vitro therapeutic efficacy of 67Ga-trastuzumab	*S. Terry, United Kingdom*
15:36	OP26 - 90Y-labeled phosphate-coated magnetic nanoparticles designed for possible medical applications	*M. Radovic, Serbia*
15:50	**Coffee Break & Poster Viewing Session**	

16:30	**Session VIII – The Art of the Drug Makers**	***C. Decristoforo, Austria / E. Janevik, Republic of Macedonia***
	European Pharmacopoeia: It is about Quality	*E. Pel, France*
	New monographs and other ongoing projects	*T. Kroon, The Netherlands*

Sunday, April 08, 2018

08:30	**Session IX – Product Scrutiny**	***H. Boersma, Netherlands / J. Aerts, Luxembourg***
08:30	Lecture 10: Preparation from generators, kits and cyclotron produced nuclides - regulatory consequences	*R. Schulze, Germany*
09:00	OP27 - Automation of FDG QC on Tracer-QC system	*A. Elizarov, Unites States*
09:12	OP28 - Simultaneous determination of the potentially toxic chemical impurities in the radiopharmaceuticals by capillary electrophoresis	*D. Antuganov, Russia*
09.24	OP29 - Evaluation of factors influencing the Ga-68 yield and Ge-68 breakthrough of a SnO2 based Gallium-68 generator	*S. Rubow, South Africa*
09:36	OP30 - iTLC Method for Analysis of 68Ga Radiophamaceuticals	*A. Larenkov, Russia*
09:48	OP31 - Optimizatzion of [18F]-FPSMA1007 Synthesis HPLC free on Fastlab platform	*E. Cazzola, Italy*
10:00	Lecture 11: Changes in radiotracer production from the beginning to beyond 2020 – did we get better?	*P. Elsinga, Netherlands*
10:30	**Coffee Break & Poster Viewing Session**	

11:00	**Session X – Seek and Destroy Revisited**	***M. Patt, Switzerland / S. Rubow, South Africa***
11:00	Lecture 12: True whole body dynamic PET - opportunities and challenges	*T. Jones, United Kingdom*
11:30	Lecture 13: Do we need radiochemists in the future?	*D. Vugts, Netherlands*
12:00	OP32 - Synthesis and evaluation of radioiodinated and astatinated prosthetic groups for bioorthogonal conjugation to antibodies for nuclear imaging and therapy	*L. Navarro, France*
12:12	OP33 - Relative biological effectiveness (RBE) of 177lutetium-NOTA-panitumumab F(ab')2 fragments for radioimmunotherapy of pancreatic cancer cell lines	*A. Boyle, Canada*
12:24	OP34 - Biological Assessment of a Radiolabelled LXXLL-Peptide for Breast Cancer Theranostics	*L. Gano, Portugal*

12:35	**Highlights / Closing**	***P. Laverman, Netherlands***

13:15	**Farewell Lunch**

POSTER PRESENTATIONS

PP01: **Optimization of Biological Quality Control of Radiochemical Precursors used for Radiopharmaceuticals Formulations – A step towards Good Radiopharmacy Practice**
A. Mitrai, India

PP02: **Production of 64Cu using indigenously developed solid target assembly in Medical Cyclotron Facility in Radiation Medicine Centre**
K. Kushwaha, India

PP03: **Microfluidic reactor in a PDMS chip for [18F]F-radiopharmaceuticals**
L. Fernandez Maza, Spain

PP04: **Development and comparison of dual generator elution methods on a MultiSyn Synthesizer (iPHASE technologies Pty Ltd) - application to the synthesis of 68Ga-peptides.**
L. Morandeau, Australia

PP05: **Radiolabelling of DTPA-silk fibroin nanoparticles with 111In for nanoparticle biodistribution studies**
T. Martinez Martinez, Spain

PP06: **First approaches to radiolabelling of silk fibroin nanoparticles with 99mTc**
T. Martinez Martinez, Spain

PP07: **Investigation of radiopharmaceutical potential of a new radiolabeled graft polymer for using the therapy and in the molecular imaging on albino wistar rats**
B. Ates, Turkey

PP08: **Production of Lutetium-177 DOTATATE/PSMA-617 on a MultiSyn radio-synthesizer module for use in Molecular Radiotherapy**
A. Asad, Australia

PP09: **Production of norepinephrine transporter tracer, [18F]NS12137, via copper-mediated nucleophilic 18F-fluorination**
S. Lahdenpohja, Finland

PP10: **Production, applications and status of zirconium-89 immunoPET Agents; an IAEA new Coordinated Research Project**
A. Jalilian, Austria

PP11: **Assay of Bacterial Endotoxins in Radiopharmaceuticals by Microplate Reader**
H. Kvaternik, Austria

PP12: **Ga-68 labeled quinazoline monomers and dimers bearing the HBED-CC chelator as PET tracers for EGFR-TK imaging**
C. Liolios, Germany

PP13: **Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPr) PET-imaging for prostate and breast cancer; tumor models and interactions with clinical relevance**
C. Liolios, Germany

PP14: **Radiolabeling of single domain antibodies with Tc-99m: evaluation of the best parameters for complexation allowing to preserve 3D conformation**
S. Bacot, France

PP15: **A comparison of four different dose calibrators using various isotopes and sample geometries**
I. Pooters, Netherlands

PP16: **A first synthesis of 11C-labelled analog of 4'-O-methylhonokiol as a potential PET radiotracer for inflammation**
M. Kiseleva, Russia

PP17: **Synthesis of WX-360-derived, uPAR-binding PET Tracers and Development of a Platform to Evaluate Their in Vitro Binding Affinities**
A. Wacker, Germany

PP18: **Fully-automated production of 2´-[18F]fluoroflumazenil without using gradient HPLC purification**
F. Trejo-Ballado, Mexico

PP19: **Radioiodination of Small Molecules and Short Peptides; the Effect of Oxidant Reagents Choice on the Radiochemical Yields**
M. Al-Qahtani, Saudi Arabia

PP20: **The Use of Nano-Sized Particles in Labelling New Class of Radiopharmaceuticals**
M. Al-Qahtani, Saudi Arabia

PP21: **Biological Investigations of a laminin Class Peptide that has a potential as a Diagnostic and Therapeutic Properties**
M. Al-Qahtani, Saudi Arabia

PP22: **Improvement of iodide and iodate identification method in the radiochemical analysis of Iodine-131 radiopharmaceutical**
N. Fukumori, Brazil

PP23: **Delivery of DTPA through liposomes as a good strategy**
M. Mougin-Degraef, France

PP24: **Validation of a clean room for the production of radiopharmaceuticals at Turku PET Centre**
S. Forsback, Finland

PP25: **Use of gravity perfusion method in PRRT: Experimental evaluation and optimization**
M. Ben Reguiga, France

PP26: **Interaction of 177LU-DOTATATE with pharmaceutical vehicles and peptides**
M. Ben Reguiga, France

PP27: **Physiological 89Zr-Oxalate Solution for PET Diagnosis: Purification, Formulation, Biological Evaluation**
A. Larenkov, Russia

PP28: **Investigation of elution of the SnO2-based 68Ge/68Ga generator with different hydrochloric acid concentrations**
S. Rubow, South Africa

PP29: **Radiolabeling Efficiency of Peptides that Interact with Overexpressed Receptors on Tumor Cells. Relevance to the Glioblastoma**
L. Malavolta, Brazil

PP30: **An automated synthesis of Ga-68 labelled ubiquicidine**
S. Rubow, South Africa

PP31: **In vitro becteria-binding assays of radiolabeled Ampicillin loaded graphene oxide nanoflakes**
F. Yurt, Turkey

PP32: **Room-temperature radiolabeling can be achieved by Al-18F chelation**
R. Pal, Korea Republic (South)

PP33: **Pd catalyzed cross-coupling for 11C-PET tracer synthesis**
H. Helbert, Netherlands

PP34: **Effect of structural forms on the stability of linear and cyclic apoptosis-targeting peptides**
Y. Su Ha, Korea Republic (South)

PP35: **Synthesis and evaluation of a [18F]fluorinated quaternary α-amino acid-based arginase inhibitor**
G. Clemente, Netherlands

PP36: **Facile synthesis of 6-L-[18F]fluoro-m-tyrosine via alcohol-enhanced Cu-mediated radiofluorination of Bpin-substituted chiral Ni-BPB-AA complex**
R. Krasikova,Russia

PP37: **Physico-chemical assessment of labeled freeze dried kits of trastuzumab-immunoconjugates significant for breast cancer therapy**
M. Sterjova, Republic of Macedonia

PP38: **Development of activity-based PET probes for selective detection of active caspase-3**
F. Elvas, Belgium

PP39: **Chemical analysis of cyclotron-based [68Ga]GaCl3 by ICP-MS**
K. Gagnon, Sweden

PP40: **Automation of Click Chemistry for the synthesis of 18F-labelled PSMA-tracers using the FlowSafe**
V. Böhmer, Netherlands

PP41: **[18F]-FEPPA, a 2nd generation of TSPO radioligand: optimized radiosynthesis and quality control**
N. Vignal, France

PP42: **Bioorthogonal chemistry applied to bispecific antibody manufacturing**
P. Le Saec, France

PP43: **A fast and robust quantification of residual solvents in radiopharmaceuticals by UHPLC**
E. Da Costa, France

PP44: **Comparison between two octreotide derivatives for somatostatin receptor scintigraphy**
A. Toumi, Tunisia

PP45: **Comparison of automated and manual labeling methods for somatostatin analogues with the example of DOTANOC and SomaKit TOC®**
A. Rauscher, France

PP46: **Optimization of automated 68Ga-PSMA-11 preparation by switch from tubing to GMP synthesizer**
L. Navarro, France

PP47: **Effective treatment of microscopic cancers with Tb-161**
Ø.A. Rusten, Norway

PP48: **Development of targeted radiopharmaceuticals with terbium-161 for use in radioimmunotherapy**
K. Eckell Skåre, Norway

PP49: **National regulations in Radiopharmacy: Is the present situation generally acceptable?**
E. Janevik-Ivanovska, Republic of Macedonia

PP50: **Optimization of production of [11C]CH3I with Methylator II for synthesis and development of 11C radiopharmaceuticals**
E. Janevik-Ivanovska, Republic of Macedonia

PP51: **Formulation and Characterization Studies of Radiolabeled, Active Folate Targeted Theranostic Co-Delivery Liposomes for Non-Small Cell Lung Cancer**
M. Karpuz-Oguz, Turkey

PP52: **HPLC method for analysis of DOTA-TOC**
P. Garnuszek, Poland

PP53: **Radiochemical purity determination of 68Ga-labelled radiopharmaceuticals.**
P. Garnuszek, Poland

VENUE OVERVIEW